AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 171 min read$FOCL

Rhodes Ryan purchased $100K of FOCL

Rhodes Ryan (Chief Executive Officer) purchased 21,000 shares of EDAP TMS SA (FOCL) at $4.75 on 2026-08-14.

Original reporting
SEC EDGAR · Rhodes Ryan
Published Aug 17, 2026, 10:01 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 17, 2026, 10:17 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$FOCL
Bullish
medium confidence
Mentioned
$FOCL
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FOCLBullishLow
01

Why it matters

The newest fact is the CEO’s open-market purchase of 21,000 shares at $4.75, with post-transaction holdings of 626,649 shares.

02

Market read

Traders may treat the insider buy as mild positive sentiment, but there is no new business or financial catalyst in the text.

03

What to watch

No 10b5-1 plan is cited, but the article also lacks context on prior holdings, compensation timing, or whether the purchase was part of a broader pattern.

Relevance 4/10Novelty 5/10Timing: filed 2026-08-17, transaction dated 2026-08-14

Background

The article is an SEC Form 4 insider transaction disclosure for EDAP TMS SA (FOCL).

Company-level read

Ticker impact

$FOCLBullishMedium confidence
Context

SEC Form 4 shows CEO Rhodes Ryan bought 21,000 shares of FOCL at $4.75 on 2026-08-14, totaling $99,750.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades unless followed by additional disclosures.

Evidence & confidence

The filing is a primary-source insider transaction, but the article provides no accompanying operational or financial news, and the size is modest relative to company-wide fundamentals.

Market effects

Sector

No sector-level implications disclosed; this is a single-company insider transaction.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider buys can be routine liquidity or diversification actions and do not guarantee improved fundamentals.

Key entities

  • issuer
    EDAP TMS SA

    Company subject of the Form 4 insider transaction disclosure.

  • insider
    Rhodes Ryan

    Chief Executive Officer and reporting insider who purchased shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

FOCL insider trading history →

Related articles

AUG 18
$FOCLMedAI 8/10

FocalTherics (FOCL) Q2 2026 Earnings Call Transcript

FocalTherics (FOCL) reported Q2 2026 earnings with $13.2M in HIFU revenue, up 39% YoY. They sold 13 Focal One systems, a 44% increase. The company expanded its footprint in the U.S. and internationally, including sales to Cleveland Clinic and Kaiser Permanente. They submitted a 510(k) application for FocalConnect and expect CMS reimbursement increases. The company is also expanding into new indications like BPH and endometriosis, targeting a $10B revenue opportunity.

yahoo.com7 min
AUG 14
$FOCLMed

FocalTherics Q2 Earnings Call Highlights

FocalTherics (NASDAQ:FOCL) reported Q2 highlights from its earnings call. U.S. Focal One procedure volumes rose 47% YoY. HIFU gross margin increased to 55.6% from 51.1%. Cash was $21.5M and it drew about €14M under its EIB credit facility. The company plans a $40M Aug. 14 offering and reiterated 2026 HIFU revenue guidance of $50M to $54M.

finance.yahoo.com6 min
AUG 13
$FOCLMedAI 8/10

FocalTherics Reports Q2 2026 Revenue of $13.2M; Net Loss $14.5M

FocalTherics (FOCL) reported Q2 2026 continuing-operations revenue of $13.2M, up 39% year over year, with gross profit of $7.3M and 55.6% gross margin. Net loss was $14.5M, or $0.39 per share. Cash was $21.5M at June 30, 2026. The company also announced an underwritten public offering for about $40M expected to close Aug. 14, 2026.

tradingview.com1 min
AUG 13
$FOCLMed

EDAP TMS SA (FOCL): Results of Operations and Financial Condition

EDAP TMS SA (FOCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FocalTherics™ Reports Second Quarter 2026 Financial Results 39% Revenue Increase and 47% Growth in U.S. Procedures AUSTIN, Texas, August 13, 2026 - FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced financial resul

SEC EDGAR 8-K6 min
AUG 12
$FOCLMed

FocalTherics Reports Preliminary Q2 2026 Results, Announces $40 Million Offering; Stock Down

FocalTherics (FOCL) reported preliminary unaudited Q2 2026 results. Revenue is expected at $12.7 to $13.2 million, up 34% to 39% from $9.7 million in Q2 2025, with gross margin at 54% to 56% versus 42.5%. Cash and investments were $21.5 million as of June 30. The company priced a public offering of 8.425M ADS at $4.75 to raise about $40M gross, with an option for 1.26375M more ADS.

rttnews.com4 min
AUG 11
$FOCLMed

EDAP TMS SA (FOCL): Results of Operations and Financial Condition

EDAP TMS SA (FOCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026 AUSTIN, Texas, August 11, 2026 - FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced preliminary unaudited financial results for the Com

SEC EDGAR 8-K6 min